5-Amino-1MQ
5-Amino-1-methylquinolinium
Oral NNMT inhibitor studied in rodents for fat-cell metabolism — no human trials exist.
Class
Nicotinamide N-methyltransferase (NNMT) inhibitor
Half-life
Not well characterised in humans
Evidence
Animal models
Animal models
Evidence comes primarily from rodent or other animal studies. Translation to humans is unproven.
Overview
5-Amino-1MQ is a small molecule rather than a peptide, but it is sold and discussed alongside metabolic peptides so it is documented here. It inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that is overexpressed in the adipose tissue of obese individuals.
The mechanistic story is coherent. NNMT consumes nicotinamide, a NAD+ precursor. Inhibiting it should raise cellular NAD+ and increase the availability of methyl donors, which in rodent studies translated to reduced fat-cell size and improved metabolic markers without changing food intake.
The gap between that story and human evidence is total. There are no published human clinical trials. Everything claimed about it in humans is extrapolation from mouse adipocyte work.
How it works
- Inhibits NNMT, an enzyme overexpressed in obese adipose tissue.
- Raises intracellular NAD+ and SAM (S-adenosylmethionine) availability.
- In rodent models, reduced adipocyte size and total fat mass without reducing caloric intake.
- Proposed downstream effects on sirtuin activity via increased NAD+.
What the research shows
Researched effects
- Reduced fat mass in diet-induced obese mice
- Increased NAD+ in adipose tissue in rodent models
- Reported improvement in muscle stem cell function in aged mice
- No human efficacy or safety data
Limitations & what it won't do
- Zero published human clinical trials.
- Not a peptide — dosing and handling differ entirely from injectables.
- Long-term effects of chronic NNMT inhibition in humans are completely unknown.
- Sold as a research chemical with no manufacturing oversight.
Dosing protocols
These ranges reflect published trials and community protocols. They are reference information, not a prescription. Doses are per injection unless noted.
Commonly cited oral protocol (no human evidence)
50–150 mgCirculated community dosing. There is no human pharmacokinetic or efficacy data to anchor this range.
Administration
Not an injectable reconstitution compound
Side effects
Common
- Reported GI upset
- Headache
- Human side-effect profile is essentially uncharacterised
Serious / rare
- Unknown — no human safety trials have been conducted
Contraindications & interactions
Do not use if you have
- Pregnant, breastfeeding, or trying to conceive
No safety data of any kind.
- Active cancer or current oncology treatment
NNMT is implicated in tumour metabolism in both directions; modulating it during active malignancy is unstudied and unwise.
Use caution if you have
- Liver disease
Hepatic metabolism of this compound in humans is uncharacterised.
- Kidney disease
Clearance pathway in humans is unknown.
What to monitor
- Liver enzymes
- Metabolic panel
- Realistic expectations — there is no human efficacy evidence
Commonly combined with
5-Amino-1MQ: common questions
Is 5-Amino-1MQ approved for human use?
Most research peptides, including 5-Amino-1MQ, are not FDA-approved for general human use and are sold as research chemicals "not for human consumption." Check the legal-status and evidence badges above, and consult a licensed physician — this page is educational only.
How strong is the evidence for 5-Amino-1MQ?
On this site 5-Amino-1MQ is graded "Animal models". Evidence comes primarily from rodent or other animal studies. Translation to humans is unproven. We grade every claim so you can weigh it honestly rather than by hype.
How is 5-Amino-1MQ reconstituted and dosed?
See the protocols and reconstitution details above for reference ranges, then use the dose calculator to convert a vial's mg, your bacteriostatic-water volume, and target dose into exact insulin-syringe units. Dosing shown is a reference, not a recommendation.
What should I screen for before considering 5-Amino-1MQ?
Run your goals, medical history, and current medications through the assessment — it flags contraindications and interactions and will hard-stop unsafe matches — and confirm everything with a licensed physician. Any use is at your own risk.
References
- Neelakantan H et al. — Selective and membrane-permeable small molecule inhibitors of NNMTBiochemical Pharmacology 2018;147:141-152
Research & educational information only — not medical advice.
You must be 18 or older to use this site. The peptides described are presented as research chemicals intended for research purposes only. Most are not approved by the FDA for human use. Dosing ranges reflect what has appeared in the scientific literature or community protocols and are not prescriptions. Nothing here replaces evaluation by a licensed physician who knows your full medical history.
Want to know if 5-Amino-1MQ fits your goals and history?
The assessment cross-checks your medical history and medications against this and every other compound before it recommends anything.
Start the assessment